MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily 20+ Yr Trsy Bull 3X ETF

ProShares Ultra Silver

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily Semicondct Bear 3X ETF

VanEck Vectors Junior Gold Miners ETF

iShares Gold Trust

GraniteShares 1.5x Long Coinbase Daily ETF

Mast Therapeutics, Inc.

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Volatility Shares Trust 2x Ether ETF

GraniteShares 1.5x Long META Daily ETF

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily Gold Miners Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

GraniteShares 2x Long AMZN Daily ETF

iShares Ethereum Trust ETF

Click Holdings Limited Ordinary Share

Foot Locker Inc.

Aytu BioPharma Inc.  Common Stock

Kindly MD Inc. Common Stock

Gryphon Digital Mining Inc Common Stock

LOBO EV TECHNOLOGIES LTD. Ordinary shares

Next Technology Holding Inc. Ordinary Shares

SolarEdge Technologies Inc. Common Stock

Siyata Mobile Inc. Common Shares

Asset Entities Inc. Class B Common Stock

Incannex Healthcare Limited American Depositary Shares

Crown LNG Holdings Limited Ordinary Shares

MicroAlgo Inc. Ordinary Shares

Luminar Technologies Inc.  Class A Common Stock

Dick's Sporting Goods Inc Common Stock

Plug Power Inc. Common Stock

Theriva Biologics Inc. Common Stock

ScanTech AI Systems Inc. Common stock

UnitedHealth Group Incorporated Common Stock (DE)

Freight Technologies Inc. Ordinary Shares

Click here to get full coverage on Why ImmunityBio, Inc. (IBRX) Soared Today - Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Soared Today  Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Soared Today - Yahoo Finance

Click here to get full coverage on ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Nasdaq

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  Nasdaq

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Nasdaq

Click here to get full coverage on ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share  TradingView

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Click here to get full coverage on ImmunityBio: Q1 Earnings Snapshot - Midland Daily News

ImmunityBio: Q1 Earnings Snapshot  Midland Daily News

ImmunityBio: Q1 Earnings Snapshot - Midland Daily News

Click here to get full coverage on Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00 - Yahoo Finance

Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00  Yahoo Finance

Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00 - Yahoo Finance

Click here to get full coverage on ImmunityBio (IBRX) Stock Rating Maintained as Buy by D. Boral Ca - GuruFocus

ImmunityBio (IBRX) Stock Rating Maintained as Buy by D. Boral Ca  GuruFocus

ImmunityBio (IBRX) Stock Rating Maintained as Buy by D. Boral Ca - GuruFocus

Click here to get full coverage on ImmunityBio: Q1 Earnings Snapshot - The Washington Post

ImmunityBio: Q1 Earnings Snapshot  The Washington Post

ImmunityBio: Q1 Earnings Snapshot - The Washington Post

Click here to get full coverage on ImmunityBio: Taking Care Of Business (NASDAQ:IBRX) - Seeking Alpha

ImmunityBio: Taking Care Of Business (NASDAQ:IBRX)  Seeking Alpha

ImmunityBio: Taking Care Of Business (NASDAQ:IBRX) - Seeking Alpha

Click here to get full coverage on Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss - marketscreener.com

Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss  marketscreener.com

Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss - marketscreener.com

Click here to get full coverage on New Analyst Forecast: $IBRX Given 'Buy' Rating - Nasdaq

New Analyst Forecast: $IBRX Given 'Buy' Rating  Nasdaq

New Analyst Forecast: $IBRX Given 'Buy' Rating - Nasdaq

Click here to get full coverage on ImmunityBio (IBRX) Q1 Revenue Matches Expectations Amid Steady G - GuruFocus

ImmunityBio (IBRX) Q1 Revenue Matches Expectations Amid Steady G  GuruFocus

ImmunityBio (IBRX) Q1 Revenue Matches Expectations Amid Steady G - GuruFocus

Click here to get full coverage on ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates  Yahoo Finance

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Yahoo Finance

ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple  Yahoo Finance

ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Yahoo Finance

Click here to get full coverage on Why ImmunityBio Inc. (IBRX) Went Up Last Week? - Yahoo Finance

Why ImmunityBio Inc. (IBRX) Went Up Last Week?  Yahoo Finance

Why ImmunityBio Inc. (IBRX) Went Up Last Week? - Yahoo Finance

Click here to get full coverage on Why ImmunityBio Inc. (IBRX) Crashed on Monday - Yahoo Finance

Why ImmunityBio Inc. (IBRX) Crashed on Monday  Yahoo Finance

Why ImmunityBio Inc. (IBRX) Crashed on Monday - Yahoo Finance

Click here to get full coverage on Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - Yahoo Finance

Why ImmunityBio Inc. (IBRX) Went Down On Tuesday?  Yahoo Finance

Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - Yahoo Finance

Click here to get full coverage on Why Did Immunitybio (IBRX) Go Down on Friday? - Yahoo Finance

Why Did Immunitybio (IBRX) Go Down on Friday?  Yahoo Finance

Why Did Immunitybio (IBRX) Go Down on Friday? - Yahoo Finance

Click here to get full coverage on Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo

Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030?  Yahoo

Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo

Click here to get full coverage on Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? - Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday?  Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? - Yahoo Finance

Click here to get full coverage on Why ImmunityBio, Inc. (IBRX) Is Skyrocketing - Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Is Skyrocketing  Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Is Skyrocketing - Yahoo Finance

Click here to get full coverage on Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight - GuruFocus

Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight  GuruFocus

Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight - GuruFocus

Click here to get full coverage on Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - Yahoo Finance

Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday?  Yahoo Finance

Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - Yahoo Finance

Click here to get full coverage on ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX) - Seeking Alpha

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX)  Seeking Alpha

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX) - Seeking Alpha

Click here to get full coverage on ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet - Yahoo Finance

Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet  Yahoo Finance

Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet - Yahoo Finance

Click here to get full coverage on Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally - Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally  Yahoo Finance

Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally - Yahoo Finance

Click here to get full coverage on ImmunityBio to Host Investor Day - Business Wire

ImmunityBio to Host Investor Day  Business Wire

ImmunityBio to Host Investor Day - Business Wire

Click here to get full coverage on Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - simplywall.st

Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts  simplywall.st

Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - simplywall.st

Click here to get full coverage on ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - PR Newswire

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment  PR Newswire

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - PR Newswire

Click here to get full coverage on ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (NASDAQ:IBRX) - Seeking Alpha

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (NASDAQ:IBRX)  Seeking Alpha

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (NASDAQ:IBRX) - Seeking Alpha

Click here to get full coverage on Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds - Yahoo Finance

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds  Yahoo Finance

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds - Yahoo Finance

Click here to get full coverage on ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch  Business Wire

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire

Click here to get full coverage on ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 20 - Yahoo Finance

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 20  Yahoo Finance

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 20 - Yahoo Finance

Click here to get full coverage on HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation - Nasdaq

HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation  Nasdaq

HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation - Nasdaq

Click here to get full coverage on ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - Yahoo Finance

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?  Yahoo Finance

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on ImmunityBio and $IBRX Investors Finalize $10.5 Million Settlement Agreement, Awaiting Court Approval - TradingView

ImmunityBio and $IBRX Investors Finalize $10.5 Million Settlement Agreement, Awaiting Court Approval  TradingView

ImmunityBio and $IBRX Investors Finalize $10.5 Million Settlement Agreement, Awaiting Court Approval - TradingView

Click here to get full coverage on IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK - Yahoo Finance

IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK  Yahoo Finance

IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK - Yahoo Finance

Click here to get full coverage on ImmunityBio, Inc. SEC 10-Q Report - TradingView

ImmunityBio, Inc. SEC 10-Q Report  TradingView

ImmunityBio, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum  Seeking Alpha

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha

Click here to get full coverage on ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor  Business Wire

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire

Click here to get full coverage on ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Yahoo Finance

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia  Yahoo Finance

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Yahoo Finance

Click here to get full coverage on ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments - Nasdaq

ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments  Nasdaq

ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments - Nasdaq

Click here to get full coverage on ImmunityBio (IBRX) Faces Filing Setback with FDA's Unanticipated Response | IBRX Stock News - GuruFocus

ImmunityBio (IBRX) Faces Filing Setback with FDA's Unanticipated Response | IBRX Stock News  GuruFocus

ImmunityBio (IBRX) Faces Filing Setback with FDA's Unanticipated Response | IBRX Stock News - GuruFocus

Click here to get full coverage on ImmunityBio (IBRX) Faces Setback with FDA Refusal for Cancer Tre - GuruFocus

ImmunityBio (IBRX) Faces Setback with FDA Refusal for Cancer Tre  GuruFocus

ImmunityBio (IBRX) Faces Setback with FDA Refusal for Cancer Tre - GuruFocus

Click here to get full coverage on IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is  GlobeNewswire

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Click here to get full coverage on Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Insider Monkey

Why ImmunityBio, Inc. (IBRX) Declined on Wednesday  Insider Monkey

Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Insider Monkey

Click here to get full coverage on ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX) - Seeking Alpha

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX)  Seeking Alpha

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX) - Seeking Alpha

Click here to get full coverage on Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Yahoo

Why ImmunityBio, Inc. (IBRX) Declined on Wednesday  Yahoo

Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Yahoo

Click here to get full coverage on Why ImmunityBio, Inc. (IBRX) Soared on Friday - Insider Monkey

Why ImmunityBio, Inc. (IBRX) Soared on Friday  Insider Monkey

Why ImmunityBio, Inc. (IBRX) Soared on Friday - Insider Monkey

Click here to get full coverage on ImmunityBio: Despite Anktiva's Clinical Promise, Remains A Difficult Investment (IBRX) - Seeking Alpha

ImmunityBio: Despite Anktiva's Clinical Promise, Remains A Difficult Investment (IBRX)  Seeking Alpha

ImmunityBio: Despite Anktiva's Clinical Promise, Remains A Difficult Investment (IBRX) - Seeking Alpha

Click here to get full coverage on ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock  Business Wire

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire

Click here to get full coverage on ImmunityBio (IBRX) Faces FDA Setback in Bladder Cancer Therapy A - GuruFocus

ImmunityBio (IBRX) Faces FDA Setback in Bladder Cancer Therapy A  GuruFocus

ImmunityBio (IBRX) Faces FDA Setback in Bladder Cancer Therapy A - GuruFocus

Click here to get full coverage on ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive - MSN

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive  MSN

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive - MSN

Click here to get full coverage on Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? - Insider Monkey

Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket?  Insider Monkey

Immunitybio Inc (IBRX)

Price Chart

Key Statistics

Technicals

About IBRX

Latest News

Why ImmunityBio, Inc. (IBRX) Soared Today - Yahoo Finance

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Nasdaq

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Advanced Charts

Top Gainers

Top Losers